Literature DB >> 33048202

Long-term outcome among females with Alport syndrome from a single pediatric center.

Selasie Goka1,2, Lawrence Copelovitch1,2, Daniella Levy Erez3,4.   

Abstract

BACKGROUND: Alport syndrome (AS) is a multisystem condition which can result in progressive kidney disease, hearing loss, and ocular changes. X-linked inheritance is observed in 85% of affected individuals. As a result, most prior studies have focused on males. Girls with AS can also be symptomatic although historically thought to have few clinical manifestations in childhood. The objective of the study was to describe the clinical presentation and course of females with AS.
METHODS: A single-center retrospective study of all young females with AS between January 1, 1987, and May 20, 2019. Subjects were identified using ICD-9/10 diagnosis codes for AS, familial hematuria, or nephritis. Clinical data were extracted by retrospective chart review.
RESULTS: Thirty-six female patients were included in the analysis. Mean age at presentation was 5.58 ± 3.0 years, and mean follow-up was 5.9 ± 3.9 years. Twenty-nine patients (80%) had a family history of AS. At end of the follow-up period, gross hematuria was observed in 15 patients (42%), 20 (56%) developed proteinuria, and 2 (6.7%) had an estimated glomerular filtration rate (eGFR) < 90 ml/min/1.73m2 with one patient developing stage 5 chronic kidney disease. Four of the twenty-seven (14.8%) who underwent audiologic testing had an abnormal exam.
CONCLUSIONS: Known family histories of AS or gross hematuria were the most common reasons for the initial presentation in our cohort. Development of proteinuria, eGFR < 90 ml/min/1.73m2, and abnormal audiology exam are not exceptional findings, suggesting that close monitoring of young females into adulthood is warranted.

Entities:  

Keywords:  Alport syndrome; Female; Hereditary nephritis; Pediatric

Mesh:

Substances:

Year:  2020        PMID: 33048202      PMCID: PMC7914153          DOI: 10.1007/s00467-020-04748-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  32 in total

1.  Alport syndrome with diffuse leiomyomatosis. When and when not?

Authors:  J H Miner
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Alport's syndrome. A report of 58 cases and a review of the literature.

Authors:  M Gubler; M Levy; M Broyer; C Naizot; G Gonzales; D Perrin; R Habib
Journal:  Am J Med       Date:  1981-03       Impact factor: 4.965

3.  Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations.

Authors:  Johanna Temme; Frederick Peters; Katharina Lange; Yves Pirson; Laurence Heidet; Roser Torra; Jean-Pierre Grunfeld; Manfred Weber; Christoph Licht; Gerhard-Anton Müller; Oliver Gross
Journal:  Kidney Int       Date:  2012-01-11       Impact factor: 10.612

4.  X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.

Authors:  Jean Philippe Jais; Bertrand Knebelmann; Iannis Giatras; Mario DE Marchi; Gianfranco Rizzoni; Alessandra Renieri; Manfred Weber; Oliver Gross; Kai-Olaf Netzer; Frances Flinter; Yves Pirson; Christine Verellen; Jörgen Wieslander; Ulf Persson; Karl Tryggvason; Paula Martin; Jens Michael Hertz; Cornelis Schröder; Marek Sanak; Sarka Krejcova; Maria Fernanda Carvalho; Juan Saus; Corinne Antignac; Hubert Smeets; Marie Claire Gubler
Journal:  J Am Soc Nephrol       Date:  2000-04       Impact factor: 10.121

5.  Aortic abnormalities in males with Alport syndrome.

Authors:  Clifford E Kashtan; Yoav Segal; Frances Flinter; David Makanjuola; Jay-Sen Gan; Terry Watnick
Journal:  Nephrol Dial Transplant       Date:  2010-05-21       Impact factor: 5.992

6.  X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome.

Authors:  Michelle N Rheault; Stefan M Kren; Linda A Hartich; Melanie Wall; William Thomas; Hector A Mesa; Philip Avner; George E Lees; Clifford E Kashtan; Yoav Segal
Journal:  Nephrol Dial Transplant       Date:  2009-10-23       Impact factor: 5.992

7.  Alport Syndrome in Women and Girls.

Authors:  Judy Savige; Deb Colville; Michelle Rheault; Susie Gear; Rachel Lennon; Sharon Lagas; Moira Finlay; Frances Flinter
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-10       Impact factor: 8.237

Review 8.  X-Linked Glomerulopathy Due to COL4A5 Founder Variant.

Authors:  Moumita Barua; Rohan John; Lorenzo Stella; Weili Li; Nicole M Roslin; Bedra Sharif; Saidah Hack; Ginette Lajoie-Starkell; Andrew L Schwaderer; Brian Becknell; Matthias Wuttke; Anna Köttgen; Daniel Cattran; Andrew D Paterson; York Pei
Journal:  Am J Kidney Dis       Date:  2017-12-01       Impact factor: 8.860

9.  Features of Autosomal Recessive Alport Syndrome: A Systematic Review.

Authors:  Jiwon M Lee; Kandai Nozu; Dae Eun Choi; Hee Gyung Kang; Ii-Soo Ha; Hae Ii Cheong
Journal:  J Clin Med       Date:  2019-02-03       Impact factor: 4.241

10.  Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome.

Authors:  Oliver Gross; Clifford E Kashtan; Michelle N Rheault; Frances Flinter; Judith Savige; Jeffrey H Miner; Roser Torra; Elisabet Ars; Constantinos Deltas; Isavella Savva; Laura Perin; Alessandra Renieri; Francesca Ariani; Francesca Mari; Colin Baigent; Parminder Judge; Bertrand Knebelman; Laurence Heidet; Sharon Lagas; Dave Blatt; Jie Ding; Yanqin Zhang; Daniel P Gale; Marco Prunotto; Yong Xue; Asher D Schachter; Lori C G Morton; Jacqui Blem; Michael Huang; Shiguang Liu; Sebastien Vallee; Daniel Renault; Julia Schifter; Jules Skelding; Susie Gear; Tim Friede; A Neil Turner; Rachel Lennon
Journal:  Nephrol Dial Transplant       Date:  2017-06-01       Impact factor: 5.992

View more
  1 in total

Review 1.  Potential Renal Damage Biomarkers in Alport Syndrome-A Review of the Literature.

Authors:  Ana Marta Gomes; Daniela Lopes; Clara Almeida; Sofia Santos; Jorge Malheiro; Irina Lousa; Alberto Caldas Afonso; Idalina Beirão
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.